- Home
- RANI vs NTRB Comparison
RANI vs NTRB Comparison
Compare RANI & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RANI
- NTRB
- Stock Information
- Founded
- RANI 2012
- NTRB 2016
- Country
- RANI United States
- NTRB United States
- Employees
- RANI N/A
- NTRB N/A
- Industry
- RANI Medicinal Chemicals and Botanical Products
- NTRB Industrial Specialties
- Sector
- RANI Health Care
- NTRB Health Care
- Exchange
- RANI Nasdaq
- NTRB Nasdaq
- Market Cap
- RANI 78.3M
- NTRB 77.9M
- IPO Year
- RANI 2021
- NTRB N/A
- Fundamental
- Price
- RANI $2.35
- NTRB $4.73
- Analyst Decision
- RANI Strong Buy
- NTRB
- Analyst Count
- RANI 5
- NTRB 0
- Target Price
- RANI $11.80
- NTRB N/A
- AVG Volume (30 Days)
- RANI 832.6K
- NTRB 19.7K
- Earning Date
- RANI 11-14-2024
- NTRB 12-11-2024
- Dividend Yield
- RANI N/A
- NTRB N/A
- EPS Growth
- RANI N/A
- NTRB N/A
- EPS
- RANI N/A
- NTRB N/A
- Revenue
- RANI N/A
- NTRB $1,803,816.00
- Revenue This Year
- RANI N/A
- NTRB N/A
- Revenue Next Year
- RANI N/A
- NTRB N/A
- P/E Ratio
- RANI N/A
- NTRB N/A
- Revenue Growth
- RANI N/A
- NTRB N/A
- 52 Week Low
- RANI $1.90
- NTRB $2.09
- 52 Week High
- RANI $8.75
- NTRB $9.60
- Technical
- Relative Strength Index (RSI)
- RANI 47.17
- NTRB 35.87
- Support Level
- RANI $2.32
- NTRB $4.68
- Resistance Level
- RANI $2.67
- NTRB $5.33
- Average True Range (ATR)
- RANI 0.17
- NTRB 0.44
- MACD
- RANI 0.01
- NTRB -0.15
- Stochastic Oscillator
- RANI 34.02
- NTRB 10.17
About RANI Rani Therapeutics Holdings Inc.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads up to 200 microlitre in liquid form with high bioavailability.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's lead product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.